Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Sanjeeb Bhandari, Vuong Nguyen, Adrian Hunt, Pierre Henry Gabrielle, Francesco Viola, Hemal Mehta, Les Manning, David Squirrell, Jennifer Arnold, Ian L. McAllister, Daniel Barthelmes, Mark Gillies

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Objectives: To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. Methods: We analysed 12-month outcomes in treatment-naïve eyes that started aflibercept or ranibizumab for nAMD (3802 eyes), DMO (975 eyes), Branch RVO (BRVO, 357 eyes), Central RVO (CRVO, 371 eyes) and Hemi-RVO (HRVO, 54 eyes) from 2015 and 2019 tracked in the prospectively designed observational Fight Retinal Blindness! Registry. Results: The mean VA change at 12-month for each year between 2015 and 2019 remained stable or otherwise showed no discernible trends over time in eyes with nAMD (+3.3 to +6 letters), DMO (+3.6 to +6.7 letters) and RVO (+10.3 to +11.7 letters for BRVO, +5.9 to +17.7 letters for CRVO and 10.2 to 20.7 letters for HRVO). The median number of VEGF-inhibitor injections in eyes that completed 12-month follow-up also remained stable at 8–9 for nAMD, 6–7 for DMO, 7–9 for RVO. Fewer eyes (<one-fourth) that started treatment between 2015 and 2018 and more eyes starting in 2019 did not complete 12-month’s follow-up visit. The mean VA in non-completers at their last visit was higher than that of their baseline visit. Conclusions: Treatment patterns and outcomes for nAMD, DMO and RVO in routine clinical practice have stabilised over the past 5 years at levels inferior to those reported by the pivotal phase 3 studies. A conscious effort to treat these conditions more intensively, or with longer lasting agents, would likely improve outcomes further in our patients.

Original languageEnglish
Pages (from-to)1145-1154
Number of pages10
JournalEye (Basingstoke)
Volume37
Issue number6
Early online date4 May 2022
DOIs
Publication statusPublished - Apr 2023

Fingerprint

Dive into the research topics of 'Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion'. Together they form a unique fingerprint.

Cite this